Ipamorelin vs CJC-1295: Mechanism, Effects, and Why They're Stacked

Ipamorelin and CJC-1295 are both growth hormone secretagogues, but they work through different receptors. Ipamorelin is a GHRP (acts on the ghrelin receptor); CJC-1295 is a GHRH analog (acts on the GHRH receptor). They're commonly stacked because activating both receptors produces a larger GH pulse than activating either alone. This article covers both compounds, their differences, side effects, and why the stack works.

For per-peptide profiles, see Ipamorelin and CJC-1295.

Quick verdict table

	Ipamorelin	CJC-1295
Class	GHRP (ghrelin receptor agonist)	GHRH analog
Mechanism	Stimulates pituitary GH release via ghrelin receptor	Stimulates pituitary GH release via GHRH receptor
Half-life	~2 hours	Without DAC: ~30 min. With DAC: ~6–8 days
Selectivity	Highly selective — minimal cortisol/prolactin spike	Selective for GHRH-R
Typical dosing	200–300 mcg, 2–3×/day SC	Without DAC: 100 mcg 1–3×/day SC. With DAC: 1–2 mg once weekly SC
Common stack partner	CJC-1295 (without DAC)	Ipamorelin
Common side effects	Very mild	Mild flushing, occasional headache
Often used for	Recovery, sleep, body comp	Body comp, sleep
Best for	First-time GH-axis user, side-effect-averse	User who wants longer-acting GH support or stack base

What each peptide actually is

Ipamorelin

A synthetic pentapeptide engineered as a selective ghrelin-receptor agonist. The selectivity is the key feature: ghrelin's other actions (hunger stimulation, cortisol and prolactin elevation) are minimized. Ipamorelin produces a clean GH pulse without the appetite spike of GHRP-6 or the cortisol/prolactin elevation of GHRP-2 and Hexarelin.

CJC-1295

A modified GHRH (growth-hormone-releasing hormone) analog. Two variants are commercially distinct:

• CJC-1295 without DAC (also called Mod GRF 1-29) — modified at four positions for stability. Half-life ~30 minutes. Used in 1–3× daily dosing, often stacked with a GHRP.
• CJC-1295 with DAC — adds a drug-affinity complex (DAC) that binds the peptide to serum albumin. Extends the active half-life to ~6–8 days. Sustained GH-axis elevation rather than discrete pulses.

The two are often confused. They produce meaningfully different physiology — without DAC gives discrete GH pulses (more physiological), with DAC gives a constant low-level elevation (less physiological).

How they differ mechanistically

GH release from the pituitary is regulated by two upstream signals:

• GHRH (from the hypothalamus) — tells the pituitary to make and release GH.
• Ghrelin (from the stomach) — amplifies the GHRH response and also produces GH release directly.

Activating only the GHRH receptor (CJC-1295 alone) produces a modest pulse. Activating only the ghrelin receptor (Ipamorelin alone) also produces a modest pulse. Activating both at the same time produces a larger pulse than the sum — the two signals amplify each other.

This is the underlying reason for the stack.

The stack: CJC-1295 (without DAC) + Ipamorelin

The most-common pattern:

• CJC-1295 without DAC 100 mcg + Ipamorelin 200–300 mcg, mixed in a single subcutaneous injection.
• 1–3× daily. The most-cited pattern is 1× before bed (amplifying the natural nocturnal GH pulse) or 2× per day (morning fasted + evening).
• 8–12 weeks on, 4 weeks off.

Either component used alone is functional. The stack just produces more GH per dose.

The CJC-1295 with DAC + Ipamorelin combination exists but is less common. The continuous GH-axis elevation from CJC-with-DAC dampens the discrete pulse benefit of co-administered Ipamorelin; the without-DAC variant pairs better.

Side effects

Ipamorelin

• Common: Very mild. Occasional injection-site irritation. Mild flushing in the first few doses.
• Less common: Headache. Lightheadedness.
• Notable absence: Negligible cortisol or prolactin spike — the cleanest GHRP in this regard.

CJC-1295

Without DAC:

• Common: Mild facial flushing at injection (the GHRH effect, harmless), occasional headache, slight tingling in extremities for a few minutes.
• Less common: Drowsiness post-dose (often desired).

With DAC:

• Common: Same as without DAC but persistent (continuous low-level effect).
• Notable: The continuous GH-axis elevation can produce more water retention and more joint discomfort than discrete pulsed dosing. Less physiological.

Stack-specific

When combined, the dominant side effects are still mild — flushing, occasional headache. The cleaner of the two GHRPs (Ipamorelin) and the cleaner pulse from without-DAC CJC-1295 keep the stack tolerable for most users.

What to expect

At reasonable doses across 8–12 weeks:

• Sleep improvement — most consistent subjective effect; amplified slow-wave sleep.
• Recovery — faster soreness clearance from training.
• Body composition — modest fat-mass reduction, small lean-mass gain. More noticeable in users training consistently than in sedentary users.
• Skin and connective tissue — fingernails grow faster; some users report skin-quality changes.

These are not steroid-tier numbers. The honest expectation: a useful adjuvant to training and recovery, not a transformation.

Who each is better for

• First-time GH-axis user — Ipamorelin alone. Cleanest profile, easiest to attribute effects to.
• Side-effect-averse — Ipamorelin alone or the stack with low-dose CJC.
• Wants larger GH pulse — the stack (CJC-1295 without DAC + Ipamorelin).
• Wants less-frequent dosing convenience — CJC-1295 with DAC, accepting the less-physiological continuous profile.
• Recovering from training-heavy weeks — the stack, dosed pre-bed.

What about Sermorelin, Hexarelin, MK-677?

	Ipamorelin	CJC-1295 (without DAC)	Sermorelin	Hexarelin	MK-677
Class	GHRP	GHRH analog	GHRH analog	GHRP	Oral GHS
Effect strength	Moderate, clean	Moderate, clean	Mild	Strong	Sustained, oral
Cortisol/prolactin spike	Negligible	Minimal	Minimal	Present	Minimal
Best for	First-time GHRP	Stack base	Mild support	Strong pulse	Oral convenience

Sermorelin is an older, milder GHRH analog. Hexarelin is a stronger GHRP but with more cortisol/prolactin elevation. MK-677 is oral, daily, and produces sustained GH-axis activation rather than discrete pulses.

For the broader landscape, see peptides for muscle growth and the muscle-growth hub.

Safety frame

GH-axis peptides require monitoring. Standard:

• Baseline IGF-1, fasting glucose, HbA1c, lipid panel.
• Repeat at 8 weeks and 16 weeks.
• Watch for: fluid retention, joint discomfort, carpal-tunnel symptoms, glucose elevation.
• Stop if any persistent symptom unexplained by other causes.

Cancer-history exclusion: IGF-1 promotes growth signaling. Anyone with personal or family cancer history should not run GH-axis peptides without oncology sign-off.

See are peptides safe? and peptide side effects.

Bottom line

• Ipamorelin and CJC-1295 (without DAC) are mechanistically complementary — different receptors, additive GH response.
• The stack is the standard pattern; either alone is functional but milder.
• Both are well-tolerated at clinical doses; Ipamorelin specifically has the cleanest side-effect profile in the GHRP class.
• Use only with monitoring; cycle don't run continuous.

Operational guides: how to reconstitute peptides, how to inject peptides, calculator, peptide cycling.